| ||||||||||
Dr. Ronald P. Rogers CHIROPRACTOR Support for your body's natural healing capabilities 270-384-5554 Click here for details 
 
Columbia Gas Dept. GAS LEAK or GAS SMELL Contact Numbers 24 hrs/ 365 days 270-384-2006 or 9-1-1 Call before you dig 
Visit ColumbiaMagazine's Directory of Churches Addresses, times, phone numbers and more for churches in Adair County Find Great Stuff in ColumbiaMagazine's Classified Ads Antiques, Help Wanted, Autos, Real Estate, Legal Notices, More... 
|
November is Diabetes Awareness Month Unless you've been living off the grid, you've probably heard about drugs like Ozempic, Mounjaro, and Wegovy, and perhaps even considered asking your doctor about them. They're all part of a class of drugs called GLP-1 receptor agonists, or just GLP-1s. According to Indiana University Health, the drugs were originally approved to help lower blood sugar, but proved exceptionally effective to help patients lose weight without the potentially risky side effects associated with drugs like phentermine. Drugmakers raced to develop newer versions that would be marketed expressly for weight loss and the first such drug, Wegovy, received approval in 2021. Since then, more GLP-1s have been approved and researchers have found that the drugs may also be useful for the prevention and treatment of heart disease -- something diabetes patients are twice as likely to develop compared to people without diabetes. And the race to develop newer and better GLP-1 drugs hasn't slowed down. According to Reuters, an experimental GLP-1 pill from Eli Lilly, called orforglipron, delivered better results than an oral version of semaglutide (developed by Novo-Nordisk) for both weight loss and blood sugar control. GLP-1s might also help reverse prediabetes. According to a study published in the journal Diabetology and Metabolic Syndrome, GLP-1s were associated with prediabetes reversal, prevention of new-onset diabetes, and lower blood sugar for 2,903 patients in 12 separate clinical trials. Many insurance plans currently cover GLP-1s for the treatment of diabetes, but not for the treatment of obesity or prediabetes. But Medicare prescription drug plans and state Medicaid programs could opt into a proposed five-year experiment that would cover off-label use of GLP-1s for members. This story was posted on 2025-10-31 23:32:33
Printable: this page is now automatically formatted for printing.
Have comments or corrections for this story? Use our contact form and let us know. More articles from topic Health Care:
Give blood at CU and receive gift cards Red Cross blood drive on Nov 19 Fast after midnight for a blood draw on Saturday KBC Blood Drive on Oct 28 October 9 is Ageism Awareness Day KNRA launches to strengthen addiction recovery ecosystem Red Cross blood drive at CU on Nov 7 Drinking water lubricates joints, stirs metabolism Improve emotions with better communication Help for choosing an OTC hearing aid View even more articles in topic Health Care |
 
115 Jamestown St. Columbia, KY. 270-384-2496 
 
  
 
 Provided by the Adair Co Fiscal Court and the Adair Co. Emergency Mgt. Agency 
|
||||||||
|
| ||||||||||
|
Quick Links to Popular Features
Looking for a story or picture? Try our Photo Archive or our Stories Archive for all the information that's appeared on ColumbiaMagazine.com. | ||||||||||
|
Contact us: Columbia Magazine and columbiamagazine.com are published by Linda Waggener and Pen Waggener, PO Box 906, Columbia, KY 42728. Please use our contact page, or send questions about technical issues with this site to webmaster@columbiamagazine.com. All logos and trademarks used on this site are property of their respective owners. All comments remain the property and responsibility of their posters, all articles and photos remain the property of their creators, and all the rest is copyright 1995-Present by Columbia Magazine. Privacy policy: use of this site requires no sharing of information. Voluntarily shared information may be published and made available to the public on this site and/or stored electronically. Anonymous submissions will be subject to additional verification. Cookies are not required to use our site. However, if you have cookies enabled in your web browser, some of our advertisers may use cookies for interest-based advertising across multiple domains. For more information about third-party advertising, visit the NAI web privacy site.
| ||||||||||
